Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.

Nestor Nivardo Jiménez-VargasYang YuDane D JensenDiana Daeun BokMatthew WisdomRocco LatorreCintya LopezJosue O Jaramillo-PolancoClaudius DegroMabel Guzman-RodriguezQuentin TsangZachary SnowBrian L SchmidtDavid E ReedAlan Edward LomaxKara Gross MargolisChristoph SteinNigel W BunnettStephen J Vanner

Published in: Gut (2021)

In a preclinical IBD model, NFEPP preferentially activates MOPr in acidified microenvironments of inflamed tissues to induce antinociception without causing respiratory depression, constipation and hyperactivity.

Keyphrases

chronic pain
pain management
ulcerative colitis
depressive symptoms
gene expression
neuropathic pain
sleep quality
cell therapy
irritable bowel syndrome
respiratory tract
spinal cord injury
binding protein
bone marrow
postoperative pain